Moreover, AnxA2-depleted mice showed extensive myofiber regeneration after laser injury, but not degeneration or adipogenic replacement, making AnxA2 a novel target to treat dysferlinopathy [194]. Here, ANXA2 is linked to neuromuscular disease caused by qualitative or quantitative defects of dysferlin.